Navigation Links
Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010
Date:9/7/2010

Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor... -- POINT RICHMOND, Calif., Sept. 7 /PRNewswire-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Banking & Financial Services, Health Care & Hospitals, Pharmaceuticals, Trade Show News Click to view news release full screen  

Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010

 

POINT RICHMOND, Calif., Sept. 7 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc.  (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that Transcept management is scheduled to participate in these upcoming investor conferences:Rodman and Renshaw Annual Global Investment ConferenceNew York, NYSeptember 14, 2010 at 5:20 p.m. EDTA live audio webcast and replay of this presentation may be accessed at http://www.wsw.com/webcast/rrshq18/tspt and on the Transcept Investor webpage at www.transcept.com.Stifel Nicolaus Healthcare ConferenceBoston, MASeptember 16, 2010 at 9:10 a.m. EDTA live audio webcast and replay of this presentation may be accessed at http://www.veracast.com/webcasts/stifel/healthcare2010/65203465.cfm and on the Transcept Investor webpage at www.transcept.com.About TransceptTranscept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. The most advanced Transcept product candidate is Intermezzo® (zolpidem tartrate sublingual tablet), for which a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in September 2008 seeking approval as a prescription sleep aid for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. In October 2009, Transcept received a Complete Response Letter from the FDA on the Intermezzo® NDA and is working to respond to issues raised in the letter. Transcept and Purdue Pharmaceutical Products L.P. have entered into a collaboration agreement for the development and commercialization of Intermezzo® in the United States.  Transcept is also developing TO-2061, an ultra low dose ondansetron augmentation therapy for patients with obsessive compulsive disorder (OCD) who have not adequately responded to treatment with SSRIs.  Transcept plans to begin a Phase 2 study of TO-2061 in 2011.  For further information, please visit the Transcept website at: www.transcept.com.

Contact:Transcept Pharmaceuticals, Inc.Greg MannDirector, Corporate Communications(510) 215-3567gmann@transcept.com
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R)
2. Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter
3. Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results
4. Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17
5. Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12
6. Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application
7. Transcept Pharmaceuticals to Report First Quarter 2009 Results
8. Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
9. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
10. Cadence Pharmaceuticals to Present at Four Investment Conferences During the Month of September 2010
11. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Feb 24, 2017 Medivir AB ... for a new Board of Directors that will be ... Nomination Committee comprises representatives of the company,s three largest ... 2016 who have accepted a seat on the Nomination ... of the 2016-2017 Nomination Committee was as follows:  ...
(Date:2/23/2017)... -- Genesis Healthcare Services has merged with Hospice Cloud, a ... Bill Monast , President and CEO of Hospice Cloud ... , executives with Home Health Depot, Inc., the parent ... This acquisition helps Hospice Cloud maintain its position as ... equipment (DME) solutions for the hospice industry. Nathan ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced the ... report to their offering. ... The latest research Menopause Drugs Price Analysis and Strategies - 2016, ... The research answers the following questions: What ... are they positioned in the Global Menopause market? What ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... 2017 , ... The California State University Institute for Palliative Care ... interested in palliative care education and research. The Symposium, “Innovate. Investigate. Educate: Advancing ... Diego on Sept. 28 and 29, 2017, on the campus of California State University ...
(Date:2/24/2017)... ... February 24, 2017 , ... Indiana Fiber Network (IFN) ... company later this year. Dyer started as the Chairman of the Management Committee ... establishment of the corporation including the recruitment of investor/owners and development of the business ...
(Date:2/24/2017)... ... February 24, 2017 , ... Congratulations to Head Over ... on February 12th. Ms. Esparza qualified into this prestigious status after winning ... in Las Vegas, Nevada. Frida is one of approximately 25 gymnasts in the ...
(Date:2/23/2017)... ... February 23, 2017 , ... On ... issued a letter to withdraw previous guidance issued by the Obama ... The guidance issued in May 2016 by the Obama Administration came in response ...
(Date:2/23/2017)... ... 23, 2017 , ... Rare Disease Report®, which is the ... Rare Disease Day events, hosted by the Rare Disease Legislative Advocates (RDLA) on ... weekly e-newsletter and quarterly publication, will be conducting interviews with patients and advocates ...
Breaking Medicine News(10 mins):